ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GRO Biosciences, a start-up cofounded by Harvard geneticist George Church in 2016, has raised another $60 million in venture funding. GRObio is developing protein therapeutics using synthetic amino acids that go beyond the 20 standard building blocks found in human biology, with the hope of treating autoimmune and other diseases. The new money will be put toward human trials of a drug candidate for refractory gout.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter